279 related articles for article (PubMed ID: 25567330)
1. Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.
; Cain LE; Phillips A; Olson A; Sabin C; Jose S; Justice A; Tate J; Logan R; Robins JM; Sterne JA; van Sighem A; Reiss P; Young J; Fehr J; Touloumi G; Paparizos V; Esteve A; Casabona J; Monge S; Moreno S; Seng R; Meyer L; Pérez-Hoyos S; Muga R; Dabis F; Vandenhende MA; Abgrall S; Costagliola D; Hernán MA
Clin Infect Dis; 2015 Apr; 60(8):1262-8. PubMed ID: 25567330
[TBL] [Abstract][Full Text] [Related]
2. Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals.
Cain LE; Caniglia EC; Phillips A; Olson A; Muga R; Pérez-Hoyos S; Abgrall S; Costagliola D; Rubio R; Jarrín I; Bucher H; Fehr J; van Sighem A; Reiss P; Dabis F; Vandenhende MA; Logan R; Robins J; Sterne JAC; Justice A; Tate J; Touloumi G; Paparizos V; Esteve A; Casabona J; Seng R; Meyer L; Jose S; Sabin C; Hernán MA;
Medicine (Baltimore); 2016 Oct; 95(41):e5133. PubMed ID: 27741139
[TBL] [Abstract][Full Text] [Related]
3. The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.
Cain LE; Phillips A; Lodi S; Sabin C; Bansi L; Justice A; Tate J; Logan R; Robins JM; Sterne JA; van Sighem A; de Wolf F; Bucher HC; Elzi L; Touloumi G; Vourli G; Esteve A; Casabona J; del Amo J; Moreno S; Seng R; Meyer L; Pérez-Hoyos S; Muga R; Abgrall S; Costagliola D; Hernán MA;
AIDS; 2012 Aug; 26(13):1691-705. PubMed ID: 22546987
[TBL] [Abstract][Full Text] [Related]
4. An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir.
Laker EAO; Nabaggala MS; Kaimal A; Nalwanga D; Castelnuovo B; Musubire A; Kiragga A; Lamorde M; Ratanshi RP
BMC Infect Dis; 2019 Mar; 19(1):280. PubMed ID: 30909871
[TBL] [Abstract][Full Text] [Related]
5. Immunological and Virological Outcomes of Patients Switched from LPV/r to ATV/r-Containing Second- Line Regimens.
Akanmu AS; Adeyemo T; Lesi F; Bello FO; Okwuegbuna K; Oloko K; Awolola A; Ogunsola FT; Okonkwo P; Kanki PJ
Curr HIV Res; 2015; 13(3):176-83. PubMed ID: 25986368
[TBL] [Abstract][Full Text] [Related]
6. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.
La Rosa AM; Harrison LJ; Taiwo B; Wallis CL; Zheng L; Kim P; Kumarasamy N; Hosseinipour MC; Jarocki B; Mellors JW; Collier AC;
Lancet HIV; 2016 Jun; 3(6):e247-58. PubMed ID: 27240787
[TBL] [Abstract][Full Text] [Related]
7. Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAzanavir & GLUcose metabolism (ATAGLU) study.
d'Ettorre G; Ceccarelli G; Zaccarelli M; Ascoli-Bartoli T; Bianchi L; Bellelli V; De Girolamo G; Serafino S; Giustini N; Mastroianni CM; Vullo V
Int J STD AIDS; 2016 Jul; 27(8):638-43. PubMed ID: 26068963
[TBL] [Abstract][Full Text] [Related]
8. Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).
Miro JM; Manzardo C; Ferrer E; Loncà M; Guardo AC; Podzamczer D; Domingo P; Curran A; Clotet B; Cruceta A; Lozano F; Pérez I; Plana M; Gatell JM;
J Acquir Immune Defic Syndr; 2015 Jun; 69(2):206-15. PubMed ID: 25831464
[TBL] [Abstract][Full Text] [Related]
9. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
10. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial.
Cohen C; Nieto-Cisneros L; Zala C; Fessel WJ; Gonzalez-Garcia J; Gladysz A; McGovern R; Adler E; McLaren C;
Curr Med Res Opin; 2005 Oct; 21(10):1683-92. PubMed ID: 16238909
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen.
Squillace N; Trabattoni D; Muscatello A; Sabbatini F; Maloberti A; Giannattasio C; Masetti M; Fenizia C; Soria A; Clerici M; Gori A; Bandera A
J Antimicrob Chemother; 2018 Aug; 73(8):2162-2170. PubMed ID: 29897513
[TBL] [Abstract][Full Text] [Related]
12. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
Swindells S; DiRienzo AG; Wilkin T; Fletcher CV; Margolis DM; Thal GD; Godfrey C; Bastow B; Ray MG; Wang H; Coombs RW; McKinnon J; Mellors JW;
JAMA; 2006 Aug; 296(7):806-14. PubMed ID: 16905786
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis.
Menshawy A; Ismail A; Abushouk AI; Ahmed H; Menshawy E; Elmaraezy A; Gadelkarim M; Abdel-Maboud M; Attia A; Negida A
Arch Virol; 2017 Aug; 162(8):2181-2190. PubMed ID: 28361290
[TBL] [Abstract][Full Text] [Related]
14. Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions.
Caniglia EC; Phillips A; Porter K; Sabin CA; Winston A; Logan R; Gill J; Vandenhende MA; Barger D; Lodi S; Moreno S; Arribas JR; Pacheco A; Cardoso SW; Chrysos G; Gogos C; Abgrall S; Costagliola D; Meyer L; Seng R; van Sighem A; Reiss P; Muga R; Hoyos SP; Braun D; Hauser C; Barrufet P; Leyes M; Tate J; Justice A; Hernán MA
J Acquir Immune Defic Syndr; 2018 Jan; 77(1):102-109. PubMed ID: 28991888
[TBL] [Abstract][Full Text] [Related]
15. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.
Aboud M; Kaplan R; Lombaard J; Zhang F; Hidalgo JA; Mamedova E; Losso MH; Chetchotisakd P; Brites C; Sievers J; Brown D; Hopking J; Underwood M; Nascimento MC; Punekar Y; Gartland M; Smith K
Lancet Infect Dis; 2019 Mar; 19(3):253-264. PubMed ID: 30732940
[TBL] [Abstract][Full Text] [Related]
16. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.
Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Wirtz V; Lataillade M; Absalon J; McGrath D;
J Acquir Immune Defic Syndr; 2010 Mar; 53(3):323-32. PubMed ID: 20032785
[TBL] [Abstract][Full Text] [Related]
17. Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy.
Calza L; Cafaggi M; Colangeli V; Borderi M; Barchi E; Lanzafame M; Nicole' S; Degli Antoni AM; Bon I; Re MC; Viale P
Infect Dis (Lond); 2018 May; 50(5):352-360. PubMed ID: 29210336
[TBL] [Abstract][Full Text] [Related]
18. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
[TBL] [Abstract][Full Text] [Related]
19. Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study.
Santoro MM; Bertoli A; Lorenzini P; Lazzarin A; Esposito R; Carosi G; Di Perri G; Filice G; Moroni M; Rizzardini G; Caramello P; Maserati R; Narciso P; Cargnel A; Antinori A; Perno CF;
AIDS Patient Care STDS; 2008 Jan; 22(1):7-16. PubMed ID: 18095835
[TBL] [Abstract][Full Text] [Related]
20. Atazanavir / ritonavir versus Lopinavir / ritonavir-based combined antiretroviral therapy (cART) for HIV-1 infection: a systematic review and meta-analysis.
Tigabu BM; Agide FD; Mohraz M; Nikfar S
Afr Health Sci; 2020 Mar; 20(1):91-101. PubMed ID: 33402897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
